BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 9637657)

  • 1. Role of the renal cysteine conjugate beta-lyase pathway in inhaled compound A nephrotoxicity in rats.
    Kharasch ED; Hoffman GM; Thorning D; Hankins DC; Kilty CG
    Anesthesiology; 1998 Jun; 88(6):1624-33. PubMed ID: 9637657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of renal cysteine conjugate beta-lyase in the mechanism of compound A nephrotoxicity in rats.
    Kharasch ED; Thorning D; Garton K; Hankins DC; Kilty CG
    Anesthesiology; 1997 Jan; 86(1):160-71. PubMed ID: 9009951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunochemical evidence against the involvement of cysteine conjugate beta-lyase in compound A nephrotoxicity in rats.
    Njoku DB; Pohl LR; Sokoloski EA; Marchick MR; Borkowf CB; Martin JL
    Anesthesiology; 1999 Feb; 90(2):458-69. PubMed ID: 9952153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nephrotoxicity of sevoflurane compound A [fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether] in rats: evidence for glutathione and cysteine conjugate formation and the role of renal cysteine conjugate beta-lyase.
    Jin L; Baillie TA; Davis MR; Kharasch ED
    Biochem Biophys Res Commun; 1995 May; 210(2):498-506. PubMed ID: 7755627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nephrotoxicity of the glutathione and cysteine S-conjugates of the sevoflurane degradation product 2-(fluoromethoxy)-1,1,3,3, 3-pentafluoro-1-propene (Compound A) in male Fischer 344 rats.
    Iyer RA; Baggs RB; Anders MW
    J Pharmacol Exp Ther; 1997 Dec; 283(3):1544-51. PubMed ID: 9400032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolism of compound A by renal cysteine-S-conjugate beta-lyase is not the mechanism of compound A-induced renal injury in the rat.
    Martin JL; Laster MJ; Kandel L; Kerschmann RL; Reed GF; Eger EI
    Anesth Analg; 1996 Apr; 82(4):770-4. PubMed ID: 8615496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of cytochrome P4503A in cysteine S-conjugates sulfoxidation and the nephrotoxicity of the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A) in rats.
    Sheffels P; Schroeder JL; Altuntas TG; Liggitt HD; Kharasch ED
    Chem Res Toxicol; 2004 Sep; 17(9):1177-89. PubMed ID: 15377151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cysteine conjugate beta-lyase-dependent biotransformation of the cysteine S-conjugates of the sevoflurane degradation product compound A in human, nonhuman primate, and rat kidney cytosol and mitochondria.
    Iyer RA; Anders MW
    Anesthesiology; 1996 Dec; 85(6):1454-61. PubMed ID: 8968194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative differences in the production and toxicity of CF2=BrCl versus CH2F-O-C(=CF2)(CF3) (compound A): the safety of halothane does not indicate the safety of sevoflurane.
    Eger EI; Ionescu P; Laster MJ; Gong D; Weiskopf RB; Kerschmann RL
    Anesth Analg; 1997 Nov; 85(5):1164-70. PubMed ID: 9356119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence for metabolism of fluoromethyl 2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A), a sevoflurane degradation product, by cysteine conjugate beta-lyase.
    Spracklin DK; Kharasch ED
    Chem Res Toxicol; 1996 Jun; 9(4):696-702. PubMed ID: 8831812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of sevoflurane on the metabolism and renal effects of compound A in rats.
    Kharasch ED; Schroeder JL; Sheffels P; Liggitt HD
    Anesthesiology; 2005 Dec; 103(6):1183-8. PubMed ID: 16306730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal cysteine conjugate beta-lyase and compound A nephrotoxicity: minimal evidence for an association.
    Njoku DB; Martin JL; Pohl LR
    Anesthesiology; 1999 Mar; 90(3):921-2. PubMed ID: 10078700
    [No Abstract]   [Full Text] [Related]  

  • 13. Cysteine conjugate beta-lyase-dependent biotransformation of the cysteine S-conjugates of the sevoflurane degradation product 2-(fluoromethoxy)-1,1,3,3,3-pentafluoro-1-propene (compound A).
    Iyer RA; Anders MW
    Chem Res Toxicol; 1997 Jul; 10(7):811-9. PubMed ID: 9250416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo nephrotoxic action of an isomeric mixture of S-(1-phenyl-2-hydroxyethyl)glutathione and S-(2-phenyl-2-hydroxyethyl)glutathione in Fischer-344 rats.
    Chakrabarti S; Malick MA
    Toxicology; 1991 Mar; 67(1):15-27. PubMed ID: 1673268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-dependent metabolism of fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A), an anesthetic degradation product, to mercapturic acids and 3,3,3-trifluoro-2-(fluoromethoxy)propanoic acid in rats.
    Kharasch ED; Jubert C; Spracklin DK; Hoffman GM
    Toxicol Appl Pharmacol; 1999 Oct; 160(1):49-59. PubMed ID: 10502502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2-Bromo-(diglutathion-S-yl)hydroquinone nephrotoxicity: physiological, biochemical, and electrochemical determinants.
    Monks TJ; Highet RJ; Lau SS
    Mol Pharmacol; 1988 Oct; 34(4):492-500. PubMed ID: 3173333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biotransformation of L-cysteine S-conjugates and N-acetyl-L-cysteine S-conjugates of the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A) in human kidney in vitro: interindividual variability in N-acetylation, N-deacetylation, and beta-lyase-catalyzed metabolism.
    Gul Altuntas T; Kharasch ED
    Drug Metab Dispos; 2002 Feb; 30(2):148-54. PubMed ID: 11792683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytotoxicity of S-conjugates of the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl) vinyl ether (Compound A) in a human proximal tubular cell line.
    Altuntas TG; Zager RA; Kharasch ED
    Toxicol Appl Pharmacol; 2003 Nov; 193(1):55-65. PubMed ID: 14613716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of low-flow sevoflurane and isoflurane effects on renal function using sensitive markers of tubular toxicity.
    Kharasch ED; Frink EJ; Zager R; Bowdle TA; Artru A; Nogami WM
    Anesthesiology; 1997 Jun; 86(6):1238-53. PubMed ID: 9197292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fate and toxicity of 2-(fluoromethoxy)-1,1,3,3,3-pentafluoro-1-propene (compound A)-derived mercapturates in male, Fischer 344 rats.
    Uttamsingh V; Iyer RA; Baggs RB; Anders MW
    Anesthesiology; 1998 Nov; 89(5):1174-83. PubMed ID: 9822006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.